Cosciens Biopharma Files May 2025 6-K Report
Ticker: CSCIF · Form: 6-K · Filed: Jun 2, 2025 · CIK: 1113423
Sentiment: neutral
Topics: foreign-private-issuer, sec-filing, routine-report
TL;DR
Cosciens Biopharma (formerly Aeterna Zentaris) filed its monthly 6-K report on May 30, 2025.
AI Summary
Cosciens Biopharma Inc. filed a Form 6-K on May 30, 2025, reporting for the month of May 2025. The company, formerly known as Aeterna Zentaris Inc. and Aeterna Laboratories Inc., is a foreign private issuer. Its principal executive office is located in Toronto, Ontario, Canada.
Why It Matters
This filing provides routine updates for Cosciens Biopharma Inc., a foreign private issuer, as required by the SEC, offering transparency to investors regarding its ongoing operations and reporting status.
Risk Assessment
Risk Level: low — This is a routine monthly filing (6-K) that does not appear to contain significant new financial or operational information.
Key Players & Entities
- COSCIENS Biopharma Inc. (company) — Filer
- Aeterna Zentaris Inc. (company) — Former company name
- AETERNA LABORATORIES INC (company) — Former company name
- Norton Rose Fulbright Canada, LLP (company) — Legal counsel/address provider
- 20250530 (date) — Report period end date
- 20250602 (date) — Filing date
FAQ
What is the primary purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer has made or is required to make public in its home country, or has distributed or is required to distribute to its security holders.
When was this specific Form 6-K filed?
This Form 6-K was filed on June 2, 2025, reporting for the month of May 2025.
What were the previous names of Cosciens Biopharma Inc.?
Cosciens Biopharma Inc. was formerly known as Aeterna Zentaris Inc. and Aeterna Laboratories Inc.
Where is the principal executive office of Cosciens Biopharma Inc. located?
The principal executive office is located at c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7.
Does Cosciens Biopharma Inc. file annual reports under Form 20-F or 40-F?
Cosciens Biopharma Inc. indicated that it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 2, 2025 regarding COSCIENS Biopharma Inc. (CSCIF).